Print
VENTURE CAPITAL:
Archimedes Does Some MathBiopharma’s funding round is the largest private European financing in 15 years.
Archimedes Pharma, a U.K.-based specialty pharma raised about $98 million and appointed a new CEO ahead of establishing U.S. commercial operations. Novo Growth Equity, funded by Novo A/S, debuted on the venture scene by leading the round, which was announced March 2. Warburg Pincus, a global private equity firm also participated. Archimedes says the funding is the largest raised by a private European biopharma company in the last 15 years. Read More
Initial Public Offerings
A Humble Start for AntheraAnthera Pharmaceuticals IPO gets done, but at just more than half of its $70 million target. Read More.Mergers and Acquisitions
Merck KgaA Outbids ThermoGerman pharmaceutical and chemical giant snaps up Millipore for $7.2 billion in a bid to diversify its revenue stream. Read More.Deals
March Roars in for Life SciencesSomething for everyone—a big acquisition, an attempt at a hostile takeover, and an anemic IPO. Read More.Initial Public Offerings
Biotech IPO a No-GoSlow deal week ends slow month for life sciences dealmaking. Read More.Deals
A Potential Blockbuster Astra nets global rights to Rigel’s RA treatment in deal worth up to $1.25 billion. Read More.Deals
Action from EuropeRigel’s $1.2 billion deal shines in an otherwise dull week, but investors less than enthusiastic about agreement. Read More.Research and Development
Crucell Beefing Up R&DVaccine maker funnels new cash into research and development. Read More.Deals
Dealmaking Takes a Breather Biotech stocks follow general market’s see-saw during the week. Read More.Initial Public Offerings
Ironwood Tests Its MettleCompany’s offering sets the mood for biotech IPOs. Read More.Deals
Biotech has its first IPO this yearCapital markets slide and dealmaking crosses borders. Read More.Deals
Gates Foundation committs $10 billion to vaccinesVenture financing and philanthropy deliver during an otherwise slow week. Read More.Deals
Seeing ValueStruggling DeCode Genetics picked up by its investors. Read More.Deals
Say What?Novartis to invest as much as $213.6 in GenVec program for hearing loss. Read More.Deals
Money MagnetBiotech is top sector for venture investment in 2009. Read More.Deals
Price Break New Illumina sequencer dramatically cuts costs. Read More.
.gif)
.gif)
.gif)
- For Many House Democrats, Cost Is the Concern
The New York Times - End-of-Life Warning at $618,616 Makes Me Wonder Was It Worth It
Bloomberg - Obama’s Health-Care Path May Face ‘War’ in Congress
Bloomberg - In Final Push, Obama Urges ‘Up-or-Down’ Vote on Health
The New York Times - Consumer group sues California health insurer
Reuters - Industry crackdown on salt could save U.S. billions
Reuters - Democrats to Press Health Bill With Simple Majority
The New York Times - Obama to Highlight Cost in New Health Bill Push
The New York Times - What do we need health insurers for anyway?
The Los Angeles Times - Obama Tells McCain ‘Election’s Over’ at Health Summit
Bloomberg